Sagimet Biosciences Inc. (SGMT) stock
SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.22−0.71 (-6.50%)
Close on Nov 13, 2026Market cap $635.26MP/E –Yield –
Earnings
Sagimet Biosciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 10, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.31
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Sagimet Biosciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 10, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026before the open | – | – | -$0.31 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 11, 2026before the open | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026before the open | – | – | -$0.33 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 11, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 13, 2025before the open | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 13, 2025before the open | – | – | -$0.32 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 12, 2025before the open | – | – | -$0.50 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024before the open | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 14, 2024before the open | – | – | -$0.25 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 15, 2024before the open | – | – | -$0.23 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 25, 2024before the open | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 13, 2023before the open | $2.00M | – | -$0.35 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 21, 2023after the close | – | – | -$35.80 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Sagimet Biosciences has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Sagimet Biosciences puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Sagimet Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Results
- Results
- Update
- Results
- Update
- Results
- Results
- Results
- Results
- Update
See a number that looks wrong?